AffiliationDepartment of Neonatology, Cork University Maternity Hospital, Wilton, Cork.
MeSHAntibodies, Monoclonal/*therapeutic use
Antibodies, Monoclonal, Humanized
Antiviral Agents/*therapeutic use
Bronchiolitis/*prevention & control/virology
Physician's Practice Patterns/*statistics & numerical data
Respiratory Syncytial Virus Infections/*prevention & control
MetadataShow full item record
CitationIr Med J. 2010 May;103(5):141-4.
JournalIrish medical journal
AbstractRespiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants. Palivizumab is an immunoprophylactic agent for RSV prevention in preterm infants and those with neonatal chronic lung disease. This study examines its use across neonatal units in Ireland. A questionnaire was administered to one Consultant Neonatologist or Paediatrician in each of the 20 maternity centres in Ireland about their guidelines for Palivizumab administration. There is variation in administration of Palivizumab with little consistency found between protocols reported in terms of age and presence of chronic lung disease. Ten centres have in house protocols, 3 centres use the American Academy of Paediatrics (AAP) guidelines, 2 centres prefer the UK Joint Committee on Vaccination and Immunisation (JCVI) guidelines and 3 centres do not have a set protocol. Four participants felt its use has impacted on hospital admissions and 61% believe its use is cost effective. The budgetary implication for immunoprophylaxis with Palivizumab in Ireland is estimated at 1.5 to 2 million euros annually. Given current pharmacoeconomic constraints there is a need to implement a national protocol on RSV immunoprophylaxis.
- Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
- Authors: Hashmi NA, Cosgrove JF, MacMahon P
- Issue date: 2000 Dec
- Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
- Authors: Fitzgerald DA
- Issue date: 2009 Sep
- Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
- Authors: Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC
- Issue date: 2004 Dec
- Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
- Authors: Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB, Burgundy Perinatal Network.
- Issue date: 2007 Mar
- Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
- Authors: Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network.
- Issue date: 2004 Dec